Vertex Surges After Drug Pair Helps in Cystic Fibrosis

June 24, 2014 2:20 PM

16 0

A combination of two Vertex Pharmaceuticals Inc. (VRTX:US) drugs improved lung function in patients with the most common form of cystic fibrosis, holding out the promise of a new treatment for the genetic illness. The stock gained the most in more than a year.

Vertex will seek regulatory approval in the fourth quarter for the treatment in the U.S. and the European Union based on the final-stage trials, dubbed TRAFFIC and TRANSPORT, the Boston-based company said in a statement today.

Read more

To category page